Effect of COVID-19 Pandemic on Presentation of Patients With Diabetic Retinopathy in a Multitier Ophthalmology Network in India

Anthony V. Das 1, Raja Narayanan 2, Padmaja K. Rani 3

1. Department of eyeSmart Electronic Medical Record (EMR) and AEye, LV Prasad Eye Institute, Hyderabad, IND
2. Department of Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, IND
3. Department of Vitreoretinal Diseases/Tele-Ophthalmology, LV Prasad Eye Institute, Hyderabad, IND

Corresponding author: Padmaja K. Rani, rpk@lvpei.org

Abstract

Objective: This study aimed to describe the demographics and clinical profile of patients with diabetic retinopathy (DR) presenting during the novel coronavirus disease 2019 (COVID-19) lockdown and unlock phases in India.

Methods: This hospital-based cross-sectional study included patients presenting from March 25, 2019, to March 31, 2021. All patients who presented with DR were included as cases. The data were collected using an electronic medical record system.

Results: In total, 88,012 patients diagnosed with retinal diseases were presented to the network and included for analysis. There were 21,271 (24%) DR patients during the study period and the majority were men (71%) from the urban area (45%). An increasing number of patients with proliferative DR (56%), sight-threatening DR (79%), need for vitreoretinal procedures (31%), and intravitreal injections (19%) were seen during the lockdown (phase one-four). There was a significant increase in the number of patients with blindness in pre-lockdown (20%), lockdown (32%), and post-lockdown (26%). Patterns of sight-threatening DR and blindness were similar in both fresh and follow-up patients.

Conclusion: The presentation of DR patients in hospital is evolving because of the COVID-19 pandemic. The footfalls of patients during the unlock (phase 1-10) regained to two-thirds of the pre-COVID-19 level. There was an increase in patients with sight-threatening DR and the need for vitreoretinal surgery and intravitreal injections during the lockdown (phase 1-4).

Introduction

The ongoing novel coronavirus disease 2019 (COVID-19) pandemic has changed the world, as we know it affecting more than 141 million individuals [1]. The past year has seen unprecedented nationwide lockdowns of populations that altered the curve of the COVID-19 cases. The Government of India enforced policies to prevent the spread of the COVID-19 virus in a population of 1.3 billion people [2]. Studies have shown that access to patient care showed a sharp decline during the lockdown period in India and that a vitreoretinal procedure was required in a third of the patients who underwent a surgical intervention [3,4]. The unlock 1.0 guidelines in India that were released from June 2020 ensured unrestricted movement of persons and goods [5]. Rath et al. shared the experience of unlock 1.0 on eyecare services which showed the highest reduction of patient footfalls in urban centers and there was no significant change in the uptake of services by gender [6]. Hanumanthadu et al. utilizing a retina diagnostic hub reported that the most common diagnosis made was diabetic retinopathy [7]. The consensus guidelines that were published for vitreoretinal diseases outlined triaging patients into urgent, semi-urgent, and delayed appointments based on the complaints and nature of the disease, provided guidelines on retinal examination techniques, retinal imaging, and prioritizing vitreoretinal surgery into emergency, semi-emergency, and elective procedures [8]. While the world is adapting to the new normal in the delivery of healthcare services, it is important to understand the trends in access to eyecare in situations such as this ongoing pandemic to identify the vulnerable groups in the population for corrective action. The authors describe a comparative report of the impact on the presentation of patients with diabetic retinopathy and other retina diseases to a large multitier ophthalmology network in India during the ongoing COVID-19 pandemic.

Materials And Methods

Study design, period, location, and approval

This cross-sectional observational hospital-based study included all patients diagnosed with retinal
disorders presenting between March 25, 2019, and March 31, 2021, to a multitier ophthalmology network located in India [9]. A standard consent form for electronic data privacy was signed by the patient or the parents or guardians of the patient at the time of registration. None of the identifiable parameters of the patient information were used for analysis of the data. The study adhered to the declaration of Helsinki and was approved by the Institutional Ethics Committee (LEC BHR-R-05-21-659). The clinical data of each patient who underwent a comprehensive ophthalmic examination was entered into a browser-based electronic medical records system (eyeSmart EMR [L V Prasad Eye Institute, Hyderabad, Telangana]) using a standardized template by trained ophthalmic personnel and supervised by an ophthalmologist [10].

Data retrieval and processing
A total of 88,012 patients of all ages diagnosed with retinal disorders presented to the network during the study period and were included in this study. The data of these patients were retrieved from the electronic medical record database and segregated in a single excel sheet (Microsoft Excel 2019 [Microsoft Corporation, Redmond, WA]). Data on patient demographics, clinical presentation, ocular diagnosis, and treatment modalities were used for analysis. The excel sheet with the required data was then used for analysis using the appropriate statistical software (Stata Statistical Software [College Station, TX: StatCorp LLC.]). Standardized definitions were used for occupation, socio-economic status, and geographic distribution [11]. The visual acuity was classified as mild or no visual impairment (20/20 to 20/70), moderate visual impairment (>20/70 to 20/200), severe visual impairment (>20/200 to 20/400), blindness category 3 (>20/400 to 20/1200), blindness category 4 (>20/1200 to perception of light), and blindness category 5 (no perception of light) according to the WHO guidelines [12]. The study duration was divided into three categories, pre-COVID-19 between March 25, 2019, and March 24, 2020, lockdown (phase 1-4) between March 25, 2021, and May 31, 2021, and unlock (phase 1-10) between June 1, 2020, and March 31, 2021 [13]. The geographic distance was classified in relation to the eye care center at presentation. The patients presenting from the same location of the eye center were classified as “intracity,” those from the same state of the eye center were classified as “intrastate,” and the rest of the patients were classified as “interstate.” A subset analysis was performed on 21,271 patients who were diagnosed with diabetic retinopathy. The clinical features of severe non-proliferative diabetic retinopathy (NPDR)/proliferative diabetic retinopathy (PDR)/diabetic macular edema (DME) were classified as sight-threatening diabetic retinopathy (STDR) [14]. The demographic distribution and clinical presentation of the patients in these three categories were used for comparative analysis.

Statistical analysis
Descriptive statistics using mean±standard deviation and median with interquartile range (IQR) were used to elucidate the demographic and clinical data using Microsoft Excel 2019.

Results
Overall, 88,012 patients diagnosed with retinal diseases presented during the study period. The most common retinal disease was diabetic retinopathy in 21,271 (24%) patients, optic nerve-related pathology in 7135 (8%), retinal detachment in 6812 (8%) patients, and vein occlusions in 6100 (7%) patients.

Diabetic retinopathy
Overall, there were 22,399 patients with diabetes mellitus who presented during the study period, of which 13,172 (59%) patients presented during pre-COVID phase, 458 (2%) patients during the lockdown, and 8769 (39%) presented during the unlock phase. Overall, 21,271 patients diagnosed with diabetic retinopathy presented during the study period. The overall mean number of patients seen per day was 28.8 (21,271/738). The patients seen during the lockdown phase were significantly lower with a mean of 6.7 (456/68) compared to the pre-COVID-19 phase with a mean of 33.5 (12,285/366) and increased to a mean of 28.1 (8530/303) during the unlock phase. The mean age of the patients was 56.59±9.44 years while the median was 57 (IQR: 39) years. The patients were primarily male 15,045 (70%) and 6226 (30%) female patients.

There were 9616 (45%) patients from the urban districts, 8799 (42%) from rural districts, and 2856 (13%) from metropolitan regions. With regards to geographic distance, 6132 (29%) patients presented from the intracity region, 10,950 (51%) patients from the state, and 4189 (20%) from outside the state. There were 18,403 (87%) patients from the paying category and 2868 (13%) from the nonpaying category. The patients presented more commonly from the states of Andhra Pradesh with 7177 (34%) patients, Telangana with 7009 (33%) patients, Odisha with 4400 (21%) patients. The most common form of diabetic retinopathy was sight-threatening diabetic retinopathy (STDR) seen in 13,875 (65%) patients, and non-sight threatening DR (NSTDR) was seen in 7396 (35%) of patients. A majority of STDR patients were fresh patients (10,914 (79%)) and 2961 (21%) were follow-up patients.

Effect of Pandemic on DR
Among the patients with diabetic retinopathy, there was an increasing trend seen during the lockdown phase
with males (75%), paying category (90%), and in patients from the intracity region (31%). There was a
decreasing trend seen in females (25%), nonpaying category (11%), and patients presenting from outside the
state (15%).

Among the patients with diabetic retinopathy, there was an increase in patients seen with proliferative
diabetic retinopathy (56%; \( p \leq 0.00001 \)) and sight-threatening diabetic retinopathy (79%; \( p = 0.001 \)) and a
decrease in patients with non-proliferative diabetic retinopathy (25%; \( p \leq 0.00001 \)) during the lockdown
phase (Figure 1). The increase in the STDR patients was seen across the pre-COVID, lockdown, and unlock
phases (Table 1).

![Bar chart showing trends of diabetic retinopathy](image)

**FIGURE 1: Comparison of trends of patients with DR and STDR during the pre-COVID-19, lockdown (phase 1-4), and unlock (phase 1-10)**

DR: diabetic retinopathy; STDR: sight-threatening diabetic retinopathy; COVID 19: coronavirus disease 2019
| Variable                  | n     | %   | Pre-COVID-19 | %   | Lockdown (phase 1-4) | %   | Unlock (phase 1-10) | %   | p-Value* |
|---------------------------|-------|-----|--------------|-----|----------------------|-----|---------------------|-----|----------|
| Total DR                  | 21,271| 100 | 12,285       | 58  | 456                  | 2   | 8530                | 40  |          |
| Gender                    |       |     |              |     |                      |     |                      |     |          |
| Male                      | 15,045| 71  | 8570         | 70  | 342                  | 75  | 6133                | 72  | 0.32     |
| Female                    | 6226  | 29  | 3715         | 30  | 114                  | 25  | 2397                | 28  | 0.07     |
| 0-30                      | 150   | 0.7 | 76           | 0.6 | 5                    | 1   | 69                  | 0.8 | 0.21     |
| 31-40                     | 760   | 3.6 | 411          | 3   | 26                   | 6   | 323                 | 4   | 0.009    |
| 41-50                     | 4464  | 21  | 2476         | 20  | 117                  | 26  | 1871                | 22  | 0.022    |
| 51-60                     | 8663  | 41  | 4949         | 40  | 187                  | 41  | 3527                | 41  | 0.84     |
| 61-70                     | 5863  | 28  | 3522         | 29  | 102                  | 22  | 2239                | 26  | 0.025    |
| 71-100                    | 1311  | 6   | 851          | 7   | 19                   | 4   | 501                 | 6   | 0.030    |
| Socio-economic status     |       |     |              |     |                      |     |                      |     |          |
| Paying                    | 18,403| 87  | 10,399       | 85  | 408                  | 90  | 7696                | 89  | 0.42     |
| Nonpaying                 | 2868  | 13  | 1886         | 15  | 48                   | 10  | 934                 | 11  | 0.013    |
| Geographic status         |       |     |              |     |                      |     |                      |     |          |
| Urban                     | 9616  | 46  | 5699         | 47  | 197                  | 43  | 3720                | 44  | 0.41     |
| Rural                     | 8799  | 41  | 4939         | 40  | 182                  | 40  | 3678                | 43  | 0.93     |
| Metropolitan              | 2856  | 13  | 1647         | 13  | 77                   | 17  | 1132                | 13  | 0.06     |
| Distance to eye care center|      |     |              |     |                      |     |                      |     |          |
| Intracity                 | 6132  | 29  | 3282         | 27  | 189                  | 41  | 2661                | 31  | <0.00001 |
| Intrastate                | 10,950| 51  | 6087         | 50  | 235                  | 52  | 4628                | 54  | 0.63     |
| Interstate                | 4189  | 20  | 2916         | 24  | 32                   | 7   | 1241                | 15  | <0.00001 |
| Type of DR                |       |     |              |     |                      |     |                      |     |          |
| NPDR                      | 8675  | 41  | 5343         | 44  | 116                  | 25  | 3216                | 38  | <0.00001 |
| PDR                       | 8170  | 38  | 4430         | 36  | 255                  | 56  | 3485                | 41  | <0.00001 |
| DME                       | 4426  | 21  | 2512         | 20  | 85                   | 19  | 1829                | 21  | 0.44     |
| STDR                      | 13,875| 65  | 7697         | 63  | 360                  | 79  | 5818                | 68  | 0.001    |
| NSTDR                     | 7396  | 35  | 4588         | 37  | 96                   | 21  | 2712                | 32  | <0.00001 |

**TABLE 1:** Comparison of baseline characteristics during the pre-COVID period, lockdown (phase 1-4), and unlocking (phase 1-10) for diabetic retinopathy patients.

*As compared to pre-COVID-19

DR: diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy; PDR: proliferative diabetic retinopathy; DME: diabetic macular edema; STDR: sight-threatening diabetic retinopathy; NSDR: non-sight threatening diabetic retinopathy; COVID 19: coronavirus disease 2019

---

**Treatment Interventions**

Among treatment interventions, there were 5091 (24%) patients who underwent vitreoretinal surgery and 3016 (14%) patients who were given intravitreal injections. A detailed comparison of all three phases is described in Table 2.
TABLE 2: Comparison of visual impairment and interventions during the pre-COVID period, lockdown (phase 1-4), and unlocking (phase 1-10) for diabetic retinopathy patients

*As compared to pre-COVID-19

COVID 19: coronavirus disease 2019

Visual Impairment and Blindness due to DR

The average logMAR decreased from 1.09±1.07 in the pre-COVID phase to 1.48±1.1 during the lockdown phase and improved to 1.24±1.1 in the unlock phase. Table 2 shows visual impairment and blindness trends among people with DR. Approximately 20% of blindness was observed before lockdown and this percentage increased to 32% during the lockdown phase and the upward trend continued with 26% blindness after the lockdown period (p<0.0001) (Table 2). These rising trends in blindness were distributed equally between fresh/follow-up patients (Table 3).
TABLE 3: Comparison of STDR, NSTDR, visual impairment, and blindness during the pre-COVID period, lockdown (phase 1-4), and unlocking (phase 1-10) for fresh and follow-up diabetic retinopathy patients

NPDR: non-proliferative diabetic retinopathy; STDR: sight-threatening diabetic retinopathy

Discussion

This study sought to describe the demographics and clinical profile of patients with diabetic retinopathy presenting during the pre-COVID-19, lockdown phase, and unlock phase in India. The findings of this study suggest that the mean footfalls of patients with diabetic retinopathy showed a sharp decline during the lockdown phase and regained to two-thirds of the pre-COVID-19 level during the unlock phase.

There was an increasing trend seen in males, higher socio-economic status and presentation from the local region. There was a decreasing trend seen in females, lower socio-economic status and presentation from outside the state. These findings suggest the need to find ways to reach patients of lower socio-economic status and women. As was the case with our study, Kavitha Singh et al. reported that people with chronic diseases, especially among the poor, rural and marginalized, have experienced challenges accessing health care [15]. We are also planning other care portals such as teleophthalmology to provide guidance and care in coordination with local ophthalmologists to patients outside the state in the future.

In an earlier study published by the same authors of their experience of patient footfalls during the lockdown, medical retina accounted for 20% and vitreoretinal procedures accounted for 14% of the emergency cases (65%) seen in the outpatient department. About a third of the patients (33%) underwent a vitreoretinal surgical intervention and the most common procedure was a retinal detachment surgery (48%) [3]. In this study, diabetic retinopathy (24%) was the most common etiology among all retinal diseases presented in hospital. The majority were patients with STDR (79%) among fresh and follow-up patients.

A simulated prediction model on impact of the COVID-19 pandemic on diabetes complications in India predicted increase in risks of 2.8% for non-proliferative diabetic retinopathy, 2.9% for proliferative diabetic retinopathy, 1.5% for retinal photocoagulation. The model showed that the duration of lockdown is directly proportional to the worsening of glycemic control and diabetes-related complications [16]. In the present study, compared to pre-lockdown phase (63%), a significant increase in number of fresh and follow-up patients presented with STDR during lockdown (79%) and post-lockdown (68%). Vitreoretinal surgical procedures showed an upward trend with respect to pre-lockdown (22%), lockdown (37%), and post-lockdown (26%). Intravitreal injections were also higher with respect to pre-lockdown (15%), lockdown (19%), and post-lockdown (16%). These increasing trends in STDR and treatment trends clearly indicate the adverse impact of the pandemic on patients with DR.

Unlike our study, studies in the United States (down 9.9%) and France reported declining trends in
In conclusion, the authors present their experience on the demographic and clinical presentation of patients with diabetic retinopathy presenting to a multi-tier ophthalmology network in India during the COVID-19 pandemic. The vulnerable patient groups of females, lower socio-economic status, and patients traveling from outside the state need focused attention in times of crisis such as this. The footfalls of patients during the lockdown phase regained to two-thirds of the pre-COVID-19 level. There was an increase in patients with sight-threatening diabetic retinopathy and the need for vitreoretinal surgery and intravitreal injections from outside the state need focused attention in times of crisis such as this. The footfalls of patients during the lockdown phase regained to two-thirds of the pre-COVID-19 level. There was an increase in patients with sight-threatening diabetic retinopathy and the need for vitreoretinal surgery and intravitreal injections.

Additional Information

Acknowledgements

The authors would like to acknowledge the support of the Department of eyeSmart EMR and AEye team specially Mr. Ranganath Vadapalli and Mr. Mohammad Pasha for their assistance in this study.

References

1. Dong E, Du H, Gardner L: An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020, 20:535-4. 10.1016/S1473-3099(20)30120-1
2. India fights corona COVID-19. (2021). Accessed: April 20, 2021: https://www.mygov.in/covid-19/?cbps=1.
3. Das AV, Narayanan R: Demographics and clinical presentation of patients with ocular disorders during the COVID-19 lockdown in India: a report. Indian J Ophthalmol. 2020, 68:1393-9. 10.4103/ijo.IJO_1171_20
4. Rathi VM, Das AV, Khanna RC: Impact of COVID-19-related lockdown on a network of rural eye centres in Southern India. Indian J Ophthalmol. 2020, 68:2596-8. 10.4103/ijo.IJO_2303_20
5. Guidelines for phased re-opening (unlock 1). (2021). Accessed: April 20, 2021: https://cdnbbr.s3waas.gov.in/s3850af92f89d9005e7a4e0559a98eccc857/uploads/2020/05/2020053020.pdf.
6. Rathn VM, Reddy RP, Fernandes M, et al.: The impact of COVID-19 ‘unlock’-1 on L V Prasad Eye Institute Network in southern India. Indian J Ophthalmol. 2021, 69:695–700. 10.4103/ijo.IJO_5145_20
7. Hanumantabhadra D, Adan K, Tinker K, Balaskas K, Hamilton R, Nicholson L: Outcomes following implementation of a high-volume medical retina virtual clinic utilising a clinician driven hub during COVID-19. Eye (Lond). 2021, 1–7. 10.1038/s41435-021-01510-4
8. Gupta V, Rajendran A, Narayanan R, et al.: Evolving consensus on managing vitreo-retina and uvea practice in post-COVID-19 pandemic era. Indian J Ophthalmol. 2020, 68:962–73. 10.4103/ijo.IJO_1404_20
9. Rao GN, Khanna RC, Atlhoj SM, Rajinikanth V, Rani PK: Integrated model of primary and secondary eye care for underserved rural areas: the L V Prasad Eye Institute experience. Indian J Ophthalmol. 2012, 60:396–400. 10.4103/0301-4738.100536
10. Das AV, Kammar P, Vadapalli R, Basu S: Big data and the eysmart electronic medical record system - An 8-year experience from a three-tier eye care network in India. Indian J Ophthalmol. 2020, 62:472–51. 10.4103/ijo.IJO_710_19
11. Das AV, Podilla S, Prashanthi GS, Basu S: Clinical profile of pterygium in patients seeking eye care in India: electronic medical records-driven big data analytics report III. Int Ophthalmol. 2020, 40:1553–63. 10.1007/s10792-020-01326-3
12. Change the definition of blindness. https://www.who.int/blindness/Change%20the%20Definition%20of%20Blindness.pdf
13. COVID-19 lockdown in India. (2021). Accessed: April 19, 2021: https://en.wikipedia.org/wiki/COVID-19_lockdown_in_India.
14. Rani PK, Raman R, Sharma V, et al.: Analysis of a comprehensive diabetic retinopathy screening model for rural and urban diabetics in developing countries. Br J Ophthalmol. 2007, 91:1425–9. 10.1136/bjo.2007.120659
15. Singh K, Kondal D, Mohan S, et al.: Health, psychosocial, and economic impacts of the COVID-19 pandemic on people with chronic conditions in India: a mixed methods study. BMC Public Health. 2021, 21:10.1186/s12889-021-10708-w
16. Ghosal S, Sinha R, Majumder M, Misra A: Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: a simulation model using multivariate regression analysis. Diabetes Metab Syndr. 2020, 14:519–25. 10.1016/j.dsx.2020.03.014
17. Ashkenazy N, Godini L, Smidley WE: Short-term effects of COVID-19-related deferral of intravitreal injection visits. Clin Ophthalmol. 2021, 15:413–7. 10.2147/OPHTHALMOS296345
18. de Gage SB, Drouin J, Desplas D, Cuenot F, Dray-Spira R, Weill A, Zureik M: Injection visits complications: a simulation model using multivariate regression analysis. Diabetes Metab Syndr. 2020, 14:319–23. 10.1007/s12889-021-10708-w
19. Ahmed I, Liu TY: The impact of COVID-19 on diabetic retinopathy monitoring and treatment. Curr Diab Rep. 2021, 21:1-5. 10.1007/s11892-021-01411-6
20. Chatziralli I, Dimitriou E, Karatzis D, Mahairoudia G, Theodossiadi G, Theodossiadi P: Effect of COVID-19-associated lockdown on patients with diabetic retinopathy. Cureus. 2021, 13:10.7759/cureus.14851
21. Naravane AV, Mundae R, Zhou Y, et al.: Short term visual and structural outcomes of anti-vascular endothelial growth factor use in France during the coronavirus disease 2019 pandemic. JAMA Ophthalmol. 2021, 159:246–2. 10.1001/jamaophthalmology.2020.5594
22. Yang KB, Feng H, Zhang H: Effects of the COVID-19 pandemic on anti-vascular endothelial growth factor treatment in China. Front Med (Lausanne). 2021, 16:10.1371/journal.pone.0247164
23. Song W, Singh RP, Rachtikaya AV: The effect of delay in care among patients requiring intravitreal injections. Ophthalmol Retina. 2021, 5:975–80. 10.1016/j.oret.2020.12.020
24. Galiero R, Pakundi PC, Nevola R, et al.: The importance of telemedicine during COVID-19 pandemic: a focus on diabetic retinopathy. J Diabetes Res. 2020, 2020:1-8. 10.1155/2020/906847
25. Teo KY, Bachmann LM, Sim D, et al.: Patterns and characteristics of a clinical implementation of a self-monitoring program for retina diseases during the COVID-19 pandemic. Ophthalmol Retina. 2021, 1–9. 10.1016/j.oret.2021.02.005
26. Kim S, Crose M, Eldridge WI, Cox B, Brown WJ, Wax A: Design and implementation of a low-cost, portable OCT system. Biomed Opt Express. 2018, 9:1232–45. 10.1116/BOE.9.001252
27. Khanna RC, Garg P, Vaddavalli PK, et al.: Response of L V Prasad Eye Institute to COVID-19 outbreak in India: experience at its tertiary eye care centre and adoption to its eye health pyramid. Int J Ophthalmol. 2021, 18:1-9. 10.18240/ijo.9.001
28. Agarwal D, Kumar A: Managing intravitreal injections in adults in COVID-19 and post-COVID-19 era-initial experiences. Indian J Ophthalmol. 2020, 68:1216–8. 10.4103/ijo.IJO_1391_20
29. Das AV, Rani PK, Vaddavalli PK: Tele-consultations and electronic medical records driven remote patient care: responding to the COVID-19 lockdown in India. Indian J Ophthalmol. 2020, 68:1007–12. 10.4103/ijo.IJO_1089_20